Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol
- PMID: 33500851
- PMCID: PMC7819280
- DOI: 10.7759/cureus.12217
Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol
Abstract
Background and objective This study involved an investigation into the pharmacokinetic and pharmacodynamic behavior of esmolol in the presence of dobutamine in healthy subjects of European ancestry. Methods We conducted a single-center, prospective randomized study of 16 healthy subjects with each receiving an infusion of dobutamine sufficient to increase heart rate (HR) by 30 beats per minute (bpm) followed by a 60-minute infusion of 50 µg/kg/min esmolol. Pharmacokinetics, HR, and blood pressure were evaluated for 180 minutes. Results In the presence of dobutamine, esmolol elimination was substantially faster than without dobutamine, Esmolol infusion reduced dobutamine-induced elevation of HR reversibly whereas the dobutamine-induced systolic blood pressure (SBP) reduction did not recover after the termination of the esmolol infusion. No serious adverse events (AEs) were observed. Conclusions The accelerated elimination of esmolol was likely due to higher cleavage through tissue esterases induced by dobutamine-induced increased tissue passage cycles per time unit. The HR effect was characteristic of a beta-blocker, whereas the blood pressure effect was likely due to a mechanism other than direct beta-blockade. HR remained elevated after the infusion of esmolol and dobutamine, most likely due to persistent blood pressure reduction.
Keywords: cardioselective β-blocker; dobutamine; esmolol; pharmacodynamics; pharmacokinetics.
Copyright © 2020, Krumpl et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures


Similar articles
-
Blood Pressure Recovery After Dobutamine Antagonism: Partial With Landiolol, None With Esmolol.Clin Pharmacol Drug Dev. 2022 Mar;11(3):309-317. doi: 10.1002/cpdd.1025. Epub 2021 Oct 16. Clin Pharmacol Drug Dev. 2022. PMID: 34655181 Clinical Trial.
-
Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults.BMC Pharmacol Toxicol. 2020 Nov 25;21(1):82. doi: 10.1186/s40360-020-00462-x. BMC Pharmacol Toxicol. 2020. PMID: 33239108 Free PMC article. Clinical Trial.
-
Symptomatic and hemodynamic recovery following dobutamine stress echo: benefit of low-dose esmolol administration.Int J Card Imaging. 1997 Feb;13(1):53-7. doi: 10.1023/a:1005710309714. Int J Card Imaging. 1997. PMID: 9080239
-
Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.Clin Pharmacokinet. 1995 Mar;28(3):190-202. doi: 10.2165/00003088-199528030-00002. Clin Pharmacokinet. 1995. PMID: 7758250 Review.
-
Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients.Heart Lung. 1988 Jan;17(1):80-9. Heart Lung. 1988. PMID: 3276651 Review.
References
-
- Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor. Jahn P, Eckrich B, Schneidrowski B, Volz-Zang C, Schulte B, Mutschler E, Palm D. https://europepmc.org/article/med/7612051. Arzneim-Forsch/Drug Res. 1995;45:536–541. - PubMed
-
- The negative inotropic effect of esmolol on isolated cardiac muscle. Arlock P, Wohlfart B, Sjöberg T, Steen S. Scand Cardiovasc J. 2005;39:250–254. - PubMed
-
- Esmolol inhibits Na+ current in rat ventricular myocytes. Deng CY, Lin SG, Zhang WC, et al. Methods Find Exp Clin Pharmacol. 2006;28:697–702. - PubMed
-
- Esmolol cardioplegia: the cellular mechanism of diastolic arrest. Fallouh HB, Bardswell SC, McLatchie LM, Shattock MJ, Chambers DJ, Kentish JC. Cardiovasc Res. 2010;87:552–560. - PubMed
-
- Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. Shibata S, Okamoto Y, Endo S, Ono K. J Pharmacol Sci. 2012;118:255–265. - PubMed
LinkOut - more resources
Full Text Sources